A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Oregon decriminalized hard drugs in 2021 and recriminalized them last month. A new analysis shows the laws likely had little ...
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
An Antidiabetic Helps the Immune System Recognize Reservoirs of HIV Sep. 10, 2024 — Metformin, a drug used to treat ... Improving HIV Treatment in Children and Adolescents -- The Right Way ...
The Institute of Human Virology of Nigeria (IHVN) is working to develop an effective HIV vaccine that will be beneficial for Nigeria ...
Novartis, which made more than $6 billion in revenue from the drug last year, says it will appeal the ruling. In other news: A study shows that people with HIV can safely receive donated kidneys from ...